Participant flow32

How many started, completed or left each group, period by period.

1 to 20 of 32

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	17
Overall Study	STARTED	Omalizumab	6
Overall Study	STARTED	MEDI4212 5 mg Subcutaneous	3
Overall Study	STARTED	MEDI4212 15 mg Subcutaneous	3
Overall Study	STARTED	MEDI4212 60 mg Subcutaneous	16
Overall Study	STARTED	MEDI4212 150 mg Subcutaneous	19
Overall Study	STARTED	MEDI4212 300 mg Subcutaneous	14
Overall Study	STARTED	MEDI4212 300 mg Intravenous	8
Overall Study	Treated	Placebo	17
Overall Study	Treated	Omalizumab	6
Overall Study	Treated	MEDI4212 5 mg Subcutaneous	3
Overall Study	Treated	MEDI4212 15 mg Subcutaneous	3
Overall Study	Treated	MEDI4212 60 mg Subcutaneous	15
Overall Study	Treated	MEDI4212 150 mg Subcutaneous	18
Overall Study	Treated	MEDI4212 300 mg Subcutaneous	14
Overall Study	Treated	MEDI4212 300 mg Intravenous	8
Overall Study	COMPLETED	Placebo	15
Overall Study	COMPLETED	Omalizumab	6
Overall Study	COMPLETED	MEDI4212 5 mg Subcutaneous	3
Overall Study	COMPLETED	MEDI4212 15 mg Subcutaneous	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01544348/flow